Voss Capital LP Purchases 57,186 Shares of REGENXBIO Inc. $RGNX

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Voss Capital LP boosted its position in shares of REGENXBIO Inc. (NASDAQ:RGNX - Free Report) by 17.2% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 390,000 shares of the biotechnology company's stock after buying an additional 57,186 shares during the period. Voss Capital LP owned approximately 0.78% of REGENXBIO worth $2,788,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in RGNX. FNY Investment Advisers LLC bought a new position in REGENXBIO during the first quarter valued at approximately $35,000. Brooklyn Investment Group boosted its stake in REGENXBIO by 163.7% during the first quarter. Brooklyn Investment Group now owns 5,583 shares of the biotechnology company's stock valued at $40,000 after buying an additional 3,466 shares during the last quarter. Pallas Capital Advisors LLC bought a new position in REGENXBIO during the first quarter valued at approximately $74,000. Laurion Capital Management LP bought a new position in REGENXBIO during the fourth quarter valued at approximately $79,000. Finally, Tower Research Capital LLC TRC boosted its stake in REGENXBIO by 442.0% during the fourth quarter. Tower Research Capital LLC TRC now owns 13,138 shares of the biotechnology company's stock valued at $102,000 after buying an additional 10,714 shares during the last quarter. 88.08% of the stock is owned by institutional investors.

REGENXBIO Trading Up 11.1%

Shares of RGNX stock traded up $0.90 on Friday, reaching $9.01. 1,355,248 shares of the company's stock were exchanged, compared to its average volume of 725,116. REGENXBIO Inc. has a 52 week low of $5.03 and a 52 week high of $13.48. The stock has a market capitalization of $455.10 million, a PE ratio of -2.62 and a beta of 1.11. The company's fifty day simple moving average is $8.52 and its 200 day simple moving average is $8.06.

REGENXBIO (NASDAQ:RGNX - Get Free Report) last issued its earnings results on Thursday, August 7th. The biotechnology company reported ($1.38) earnings per share for the quarter, missing analysts' consensus estimates of ($1.13) by ($0.25). The firm had revenue of $21.36 million for the quarter, compared to the consensus estimate of $40.87 million. REGENXBIO had a negative net margin of 112.70% and a negative return on equity of 66.95%. As a group, sell-side analysts predict that REGENXBIO Inc. will post -4.84 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of brokerages recently commented on RGNX. Barclays dropped their price target on REGENXBIO from $50.00 to $37.00 and set an "overweight" rating for the company in a research note on Friday, August 8th. HC Wainwright reaffirmed a "buy" rating and issued a $34.00 price objective on shares of REGENXBIO in a research note on Tuesday, August 19th. Wall Street Zen lowered REGENXBIO from a "hold" rating to a "strong sell" rating in a research note on Saturday, August 9th. Chardan Capital reaffirmed a "buy" rating and issued a $52.00 price objective on shares of REGENXBIO in a research note on Friday, August 8th. Finally, Royal Bank Of Canada lowered their price objective on REGENXBIO from $21.00 to $17.00 and set an "outperform" rating for the company in a research note on Friday, August 8th. Five analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $28.38.

REGENXBIO Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.